dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Tec family (type: enzyme)
Target: TXK tyrosine kinase

Ligand: PRN694 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.850000381469727 pIC50
Reference (Journal): Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.
Published in: J Biol Chem

Ligand: ibrutinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2013), EMA (2014)
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Published in: N Engl J Med

Ligand: compound 9 [PMID: 26006010] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.389999866485596 pIC50
Reference (Journal): Prolonged and tunable residence time using reversible covalent kinase inhibitors.
Published in: Nat Chem Biol

Ligand: compound 7 [PMID: 22464456] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.110000133514404 pIC50
Reference (Journal): X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.
Published in: Bioorg Med Chem Lett

Ligand: compound 38 [PMID: 24915291] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.850000381469727 pIC50
Reference (Journal): Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
Published in: J Med Chem

Ligand: compound 31 [PMID: 24915291] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.720000267028809 pIC50
Reference (Journal): Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
Published in: J Med Chem

Ligand: compound 23 [PMID: 17600705] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pIC50
Reference (Journal): N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics.
Published in: Bioorg Med Chem Lett

Ligand: bosutinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2012), EMA (2013)
Primary target: no
Median affinity: 9.520000457763672 pIC50
Reference (Journal): Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Published in: Leukemia

Ligand: acalabrutinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2017), EMA (2020)
Primary target: no
Median affinity: 6.429999828338623 pIC50
Reference (Journal): Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Published in: N Engl J Med
Target family: TESK subfamily (type: enzyme)
Target: testis associated actin remodelling kinase 1

Ligand: compound 30 [PMID: 22902653] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.949999809265137 pIC50
Reference (Journal): Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
Published in: Bioorg Med Chem Lett
Target family: TESK subfamily (type: enzyme)
Target: testis associated actin remodelling kinase 2

Ligand: compound 30 [PMID: 22902653] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.380000114440918 pIC50
Reference (Journal): Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
Published in: Bioorg Med Chem Lett
Target family: TESK subfamily (type: enzyme)
Target: testis associated actin remodelling kinase 1

Ligand: compound 35 [PMID: 22902653] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.519999980926514 pIC50
Reference (Journal): Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
Published in: Bioorg Med Chem Lett

Ligand: compound 31 [PMID: 22902653] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.340000152587891 pIC50
Reference (Journal): Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
Published in: Bioorg Med Chem Lett
Target family: TESK subfamily (type: enzyme)
Target: testis associated actin remodelling kinase 2

Ligand: compound 35 [PMID: 22902653] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.519999980926514 pIC50
Reference (Journal): Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
Published in: Bioorg Med Chem Lett

Ligand: compound 31 [PMID: 22902653] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.599999904632568 pIC50
Reference (Journal): Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
Published in: Bioorg Med Chem Lett
Target family: Testis specific kinase (TSSK) family (type: enzyme)
Target: testis specific serine kinase 1B

Ligand: compound 20 [PMID: 30998356] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.659999847412109 pIC50
Reference (Journal): Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
Published in: J Med Chem

Ligand: ceritinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2014), EMA (2015)
Primary target: no
Median affinity: 7.639999866485596 pIC50
Reference (Journal): Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.
Published in: J Med Chem
Target family: Testis specific kinase (TSSK) family (type: enzyme)
Target: testis specific serine kinase 2

Ligand: compound 2c [PMID: 24900538] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.510000228881836 pIC50
Reference (Journal): Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors.
Published in: ACS Med Chem Lett
Target family: Tetraspanins (type: other_protein)
Target: CD37 molecule

Ligand: lilotomab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 8.569999694824219 pKd
Reference (Journal): Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
Published in: Anticancer Res

Ligand: naratuximab emtansine (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.300000190734863 pEC50
Reference (Journal): A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
Published in: Blood

Ligand: otlertuzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
Published in: MAbs
Target family: Thyroid hormone turnover (type: enzyme)
Target: thyroid peroxidase

Ligand: methimazole (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1950)
Primary target: yes
Median affinity:  -
Reference (Journal): Mechanism of action of thioureylene antithyroid drugs: factors affecting intrathyroidal metabolism of propylthiouracil and methimazole in rats.
Published in: Endocrinology

Ligand: propylthiouracil (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1947)
Primary target: yes
Median affinity:  -
Reference (Journal): Mechanism of action of thioureylene antithyroid drugs: factors affecting intrathyroidal metabolism of propylthiouracil and methimazole in rats.
Published in: Endocrinology

Ligand: mitiperstat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.159999847412109 pIC50
Reference (Journal): Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.
Published in: J Med Chem
Target family: Thyrotropin-releasing hormone receptors (type: gpcr)
Target: TRH<sub>1</sub> receptor

Ligand: chlordiazepoxide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1960)
Primary target: no
Median affinity: 4.820000171661377 pKi
Reference (Journal): Use of receptor antagonist in elucidating the mechanism of action of TRH in GH3 cells.
Published in: Ann N Y Acad Sci

Ligand: diazepam (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1986)
Median affinity: 5.15 pKi
Reference (Journal): Use of receptor antagonist in elucidating the mechanism of action of TRH in GH3 cells.
Published in: Ann N Y Acad Sci

Ligand: MeTRH (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity: 8.5 pKi
Reference (Journal): Synthetic TRF (thyrotropin releasing factor) analogues. II. pGlu-N3imMe-His-Pro-NH2: a synthetic analogue with specific activity greater than that of TRF2.
Published in: Endocrinology

Ligand: midazolam (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2000), EMA (2011)
Primary target: no
Median affinity: 5.489999771118164 pKi
Reference (Journal): Use of receptor antagonist in elucidating the mechanism of action of TRH in GH3 cells.
Published in: Ann N Y Acad Sci

Ligand: chlordiazepoxide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1960)
Primary target: no
Median affinity: 4.699999809265137 pKi
Reference (Journal): Expression cloning of a cDNA encoding the mouse pituitary thyrotropin-releasing hormone receptor.
Published in: Proc Natl Acad Sci USA
Target family: Thyrotropin-releasing hormone receptors (type: gpcr)
Target: TRH<sub>2</sub> receptor

Ligand: TRH (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1976)
Median affinity: 7.4 pKi
Reference (Journal): Molecular and cellular biology of thyrotropin-releasing hormone receptors.
Published in: Physiol Rev

Ligand: taltirelin (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.9 pKi
Reference (Journal): Thyrotropin-releasing hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin actions in the CNS of mice.
Published in: Neuropsychopharmacology
Target family: Thyrotropin-releasing hormone receptors (type: gpcr)
Target: TRH<sub>1</sub> receptor

Ligand: [3H]MeTRH (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity: 8.5 pKd
Reference (Journal): Preparation of 3H-[3-M3-His2]TRH as an improved ligand for TRH receptors.
Published in: Neuroendocrinology

Ligand: taltirelin (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.5 pKi
Reference (Journal): Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor.
Published in: Front Endocrinol (Lausanne)

Ligand: TRH (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1976)
Primary target: yes
Median affinity: 7.400000095367432 pKi
Reference (Journal): Molecular and cellular biology of thyrotropin-releasing hormone receptors.
Published in: Physiol Rev
Target family: Thyrotropin-releasing hormone receptors (type: gpcr)
Target: TRH<sub>2</sub> receptor

Ligand: MeTRH (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity: 8.9 pKi
Reference (Journal): Thyrotropin-releasing hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin actions in the CNS of mice.
Published in: Neuropsychopharmacology

Ligand: [3H]MeTRH (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity: 8.5 pKd
Reference (Journal): Preparation of 3H-[3-M3-His2]TRH as an improved ligand for TRH receptors.
Published in: Neuroendocrinology
Target family: TIF1 family (type: enzyme)
Target: tripartite motif containing 24

Ligand: dTRIM24 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.46999979019165 pIC50
Reference (Journal): Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands.
Published in: Nat Chem Biol

Ligand: compound 34 [PMID: 25974391] (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 6.650000095367432 pKd
Reference (Journal): Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF.
Published in: J Med Chem
Target family: TKL-unique family (type: enzyme)
Target: mixed lineage kinase domain like pseudokinase

Ligand: compound 56 [PMID: 36136378] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.090000152587891 pEC50
Reference (Journal): Discovery of a New Class of Uracil Derivatives as Potential Mixed Lineage Kinase Domain-like Protein (MLKL) Inhibitors.
Published in: J Med Chem

Ligand: MLKL compound 1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death.
Published in: Proc Natl Acad Sci USA

Ligand: MLKL compound 1 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 5.03000020980835 pKd
Reference (Journal): Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death.
Published in: Proc Natl Acad Sci USA
Target family: Toll-like receptor family (type: catalytic_receptor)
Target: TLR8

Ligand: resiquimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.210000038146973 pEC50
Reference (Journal): Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.
Published in: Nat Immunol

Ligand: selgantolimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.659999847412109 pEC50
Reference (Journal): Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
Published in: J Med Chem
Target family: Toll-like receptor family (type: catalytic_receptor)
Target: TLR9

Ligand: agatolimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): CpG 7909: PF 3512676, PF-3512676.
Published in: Drugs R D

Ligand: hydroxychloroquine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1955)
Primary target: yes
Median affinity: 7.099999904632568 pIC50
Reference (Journal): Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo.
Published in: Mol Pharmacol
Target family: Toll-like receptor family (type: catalytic_receptor)
Target: TLR7

Ligand: loxoribine (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Reference (Journal): The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily.
Published in: Eur J Immunol

Ligand: imiquimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1997), EMA (1998)
Primary target: yes
Median affinity: 4.940000057220459 pEC50
Reference (Journal): Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
Published in: ACS Med Chem Lett

Ligand: resiquimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.869999885559082 pEC50
Reference (Journal): Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.
Published in: Nat Immunol

Ligand: resiquimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.869999885559082 pEC50
Reference (Journal): Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.
Published in: Nat Immunol

Ligand: resiquimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.869999885559082 pEC50
Reference (Journal): Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
Published in: ACS Med Chem Lett
Target family: Toll-like receptor family (type: catalytic_receptor)
Target: TLR8

Ligand: 3M-002 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 5.880000114440918 pEC50
Reference (Journal): Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines.
Published in: J Med Chem

Ligand: compound 12p [Larson et al., 2017] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 5.300000190734863 pEC50
Reference (Journal): Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
Published in: ACS Med Chem Lett

Ligand: compound 15 [PMID: 35450354] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an <i>In Vivo</i> Efficacious TLR7/8 Antagonist.
Published in: ACS Med Chem Lett

Ligand: CU-CPT8m (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.659999847412109 pKd
Reference (Journal): Small-molecule inhibition of TLR8 through stabilization of its resting state.
Published in: Nat Chem Biol

Ligand: CU-CPT8m (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.170000076293945 pIC50
Reference (Journal): Small-molecule inhibition of TLR8 through stabilization of its resting state.
Published in: Nat Chem Biol

Ligand: motolimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7 pEC50
Reference (Journal): VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
Published in: Clin Cancer Res

Ligand: resiquimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.210000038146973 pEC50
Reference (Journal): Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
Published in: ACS Med Chem Lett

Ligand: resiquimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.210000038146973 pEC50
Reference (Journal): Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.
Published in: Nat Immunol
Target family: Toll-like receptor family (type: catalytic_receptor)
Target: TLR2

Ligand: defoslimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.
Published in: Eur J Pharmacol

Ligand: compound 13 [PMID: 23098072] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.599999904632568 pKi
Reference (Journal): Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.
Published in: J Med Chem
Target family: Toll-like receptor family (type: catalytic_receptor)
Target: TLR7

Ligand: hydroxychloroquine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1955)
Primary target: yes
Median affinity: 5.559999942779541 pIC50
Reference (Journal): Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo.
Published in: Mol Pharmacol
Target family: Toll-like receptor family (type: catalytic_receptor)
Target: TLR2

Ligand: diprovocim-1 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.960000038146973 pEC50
Reference (Journal): Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.
Published in: J Am Chem Soc

Ligand: peptidoglycan (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2.
Published in: J Immunol

Ligand: peptidoglycan (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2.
Published in: J Biol Chem

Ligand: tomaralimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pKd
Reference (Patent): Humanised antibodies to toll-like receptor 2 and uses thereof

Ligand: tomaralimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 7.539999961853027 pKd
Reference (Patent): Humanised antibodies to toll-like receptor 2 and uses thereof
Target family: Toll-like receptor family (type: catalytic_receptor)
Target: TLR3

Ligand: poly(I:C) (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.
Published in: Nature